Mario Castro, MD
Pulmonary Disease · Kansas City, KSNPI 1881610004
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,228,904 of the $1,864,951 with a category attached, or 65.9%. 26 manufacturers reported payments, led by Sanofi at 43.8% of the total. Among pulmonary disease clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,316 payments — averaging $1417.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$817K
- AstraZeneca$470K
- Regeneron Healthcare Solutions, Inc.$245K
- Teva Pharmaceuticals USA, Inc.$105K
- Sanofi-aventis U.S. LLC$40K
- GSK$39K
- plus $149K from 20 others
Across 416 payments — averaging $4902.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galvanize Therapeutics, Inc$621K
- AstraZeneca$384K
- Sanofi US Services Inc.$227K
- Astrazeneca UK Limited$218K
- Regeneron$215K
- Sanofi$102K
- plus $271K from 7 others
What the payments were for
- Consulting fees$380,90920%
- Speaking & faculty fees$1,228,90466%
- Grants$3,0000%
- Travel & lodging$226,65712%
- Food & beverage$25,4811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 446 | $816,575 |
| AstraZeneca | 415 | $469,922 |
| Regeneron Healthcare Solutions, Inc. | 207 | $245,135 |
| Teva Pharmaceuticals USA, Inc. | 80 | $105,493 |
| Sanofi-aventis U.S. LLC | 13 | $39,578 |
| GSK | 36 | $39,354 |
| Genentech USA, Inc. | 27 | $30,578 |
| Amgen | 25 | $30,147 |
| Merck | 16 | $21,134 |
| Astrazeneca UK Limited | 6 | $16,127 |
| Sanofi Pasteur Inc. | 4 | $13,813 |
| Sanofi US Services Inc. | 3 | $6,856 |
| Polarean, Inc. | 9 | $6,007 |
| Mylan Specialty L.p. | 5 | $5,768 |
| Regeneron | 10 | $4,730 |
| Pfizer | 3 | $4,500 |
| Novartis | 2 | $3,196 |
| Chiesi USA, Inc. | 1 | $3,000 |
| Boehringer Ingelheim | 1 | $2,180 |
| Mylan Inc. | 1 | $436 |
| Siemens Medical Solutions USA, Inc. | 1 | $167 |
| Biocryst US Sales Co., LLC | 1 | $148 |
| Incyte Corporation | 1 | $60 |
| Atricure, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $14 |
| Electromed, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$626,151
- FASENRA$242,504
- TEZSPIRE$128,223
- CINQAIR$84,243
- NUCALA$28,461
- XOLAIR$16,747
- ProAir Digihaler$13,925
- AirDuo Digihaler$8,395
- Yupelri$6,094
- XENOVIEW$5,844
- SPIRIVA$2,180
- ArmonAir Digihaler$1,845
- NAEOTOM Alpha$167
- MAGNETOM Altea$167
- Orladeyo$148
How this compares
$1,864,951 in reported general payments places this provider in the 95th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 19 | $78,723 |
| Dupixent PenDupilumab | 14 | $50,025 |
| Dupixent SyringeDupilumab | 11 | $35,548 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $25,126 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $17,422 |
| Spiriva RespimatTiotropium Bromide | 26 | $15,979 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $11,841 |
| DuleraMometasone/Formoterol | 16 | $8,161 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,345 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,129 |
| DalirespRoflumilast | 11 | $4,887 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $3,208 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,640 |
| Roflumilast | 11 | $544 |
| Azithromycin | 20 | $295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort, Daliresp | $469,922 | $89,95443 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $39,354 | $47,67788 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $2,180 | $27,81945 claims |
| MerckDulera | $21,134 | $8,16116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Kansas City
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
- Heath LathamKansas City$15K
- Kyle BrownbackKansas City$15K
- Michelle HomanKansas City$8K
- Aman KhanKansas City$5K
- Damien StevensKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.